FDA Determines Regulatory Review Period for SAPIEN TRANSCATHETER HEART VALVE Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the SAPIEN TRANSCATHETER HEART VALVE medical device, as required by law, following a patent extension application submitted to the US Department of Commerce.